By the Top Tier Newswire AI Desk · October 6, 2026 at 9:55 AM ET · reviewed against 37 wire stories
VAXCYTE INC (PCVX) is down -12.02% in the latest session. Our newswire has captured 37 stories on PCVX across 16 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
PCVX stock is down 12.02% to $64.95 in the session, marking a sharp reversal from its recent price surge. The decline follows the company’s announcement of a $1 billion dual offering of common stock and convertible senior notes. The move has raised concerns about equity dilution and triggered a rapid sell-off in the stock, despite earlier positive phase 3 trial results for its pneumococcal vaccine.
What Happened
Vaxcyte announced on Monday that it filed to sell $500 million of common stock and $500 million of convertible senior notes. The offering comes after the company reported that its VAX-31 pneumococcal vaccine met all primary endpoints in a pivotal phase 3 trial for adults 50 and older. However, the stock opened with a 2.9% gap down and continued to fall throughout the session, reaching a low of $64.56. The stock’s decline reflects investor concerns over the large-scale capital raise, which could dilute existing shareholders. The offering was widely covered in the market, with 37 stories from 16 sources in the last 36 hours. BofA had raised the price target for Vaxcyte to $146 from $130 earlier in the week, but the stock’s sharp drop suggests that the market is prioritizing caution over optimism.
What The Data Shows
The intraday session showed a volatile start, with the stock opening at $71.68 and peaking at $73.39 before falling sharply. Volume has reached 1.1 million shares, which is 0.8 times the 3-month average. The stock is now trading near its 52-week low of $39.87, having previously surged 30.4% over the last eight sessions. The 52-week tape also noted 13 fresh 52-week lows on October 6. Recent insider transactions show seven sales totaling $3.1 million in the last 90 days, with no insider buys. Congressional trades show two small purchases in the last 90 days. Unusual options activity includes two notable prints, with $70,000 in call premiums and no put premiums.
What To Watch
The stock’s next catalyst will likely be its upcoming earnings report, if any, or further updates on the VAX-31 vaccine development. Coverage breadth remains high, with continued attention on the offering and trial results. Investors will be watching for any follow-up data or regulatory developments that could stabilize or reverse the stock’s downward trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BofA raises Vaxcyte stock price target to $146 on OPUS-1 data
BofA raises Vaxcyte stock price target to $146 on OPUS-1 data
45d agoInvesting.com MarketsBEARISH 42General
Why is Vaxcyte stock sliding today?
Why is Vaxcyte stock sliding today?
45d agoStocktwits NewsBULLISH 67Product/PR
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
45d agoInvesting.com MarketsBEARISH 34General
Why is Vaxcyte stock sliding in after-hours trading today?
Why is Vaxcyte stock sliding in after-hours trading today?
45d agoInvesting.com MarketsBEARISH 28General
Vaxcyte stock falls on $1B dual offering launch
Vaxcyte stock falls on $1B dual offering launch
45d agoThe FlyBEARISH 24General
Vaxcyte files to sell $500M of common stock, $500M of convertible senior notes
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →